pharma news today obesity drugs glp-1 october 2025 health Outlook for obesity in 2025: more The Obesity Drug Boom

In those with monocular vision or prior NAION, discuss risks explicitly but do not withhold therapy solely on this basis

Conclusions GLP-1 agonists are associated with significant pancreatitis risk which increases with larger cumulative doses.

Four weeks ago, I wrote about my decision to undertake a weight-loss journey using a GLP-1 (a semagl

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have been studied for their cardiovascular benefits in type 2 diabetes

Medical Coding & Billing Guidelines for GLP-1 Medications What Coders Need to Know About Coverage, Documentation, and Compliance Glucagon-Like

Learn about the benefits and practical steps for transitioning patients from GLP-1 RAs to dual GLP-1/GIP receptor agonists, such as tirzepatide, to improve glycemic control in adults with type 2 diabetes.